prikaz prve stranice dokumenta Increased Risk-Taking Behaviour and Brain-Derived Neurotrophic Factor Val66Met Polymorphism Correlates to Decreased Serum Brain-Derived Neurotrophic Factor Level in Heroin Users
Access restricted to all Croatian higher education institution's students and staff
Scientific paper - Original scientific paper
Increased Risk-Taking Behaviour and Brain-Derived Neurotrophic Factor Val66Met Polymorphism Correlates to Decreased Serum Brain-Derived Neurotrophic Factor Level in Heroin Users
European Addiction Research, 24 (2018), 4; 189-200. urn:nbn:hr:184:728216
Roviš, Darko; Černelič Bizjak, Maša; Vasiljev Marchesi, Vanja; Petelin, Ana; Jenuš, Tina; Vidic, Suzana; Drevenšek, Gorazd; Jenko Pražnikar, Zala

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Roviš, D., Černelič Bizjak, M., Vasiljev Marchesi, V., Petelin, A., Jenuš, T., Vidic, S. ... Jenko Pražnikar, Z. (2018). Increased Risk-Taking Behaviour and Brain-Derived Neurotrophic Factor Val66Met Polymorphism Correlates to Decreased Serum Brain-Derived Neurotrophic Factor Level in Heroin Users. European Addiction Research, 24. (4), 189-200. Retrieved from https://urn.nsk.hr/urn:nbn:hr:184:728216

Roviš, Darko, et al. "Increased Risk-Taking Behaviour and Brain-Derived Neurotrophic Factor Val66Met Polymorphism Correlates to Decreased Serum Brain-Derived Neurotrophic Factor Level in Heroin Users." European Addiction Research, vol. 24, no. 4, 2018, pp. 189-200. https://urn.nsk.hr/urn:nbn:hr:184:728216

Roviš, Darko, Maša Černelič Bizjak, Vanja Vasiljev Marchesi, Ana Petelin, Tina Jenuš, Suzana Vidic, Gorazd Drevenšek and Zala Jenko Pražnikar. "Increased Risk-Taking Behaviour and Brain-Derived Neurotrophic Factor Val66Met Polymorphism Correlates to Decreased Serum Brain-Derived Neurotrophic Factor Level in Heroin Users." European Addiction Research 24, no. 4 (2018): 189-200. https://urn.nsk.hr/urn:nbn:hr:184:728216

Roviš, D., et al. (2018) 'Increased Risk-Taking Behaviour and Brain-Derived Neurotrophic Factor Val66Met Polymorphism Correlates to Decreased Serum Brain-Derived Neurotrophic Factor Level in Heroin Users', European Addiction Research, 24(4), pp. 189-200. Available at: https://urn.nsk.hr/urn:nbn:hr:184:728216 (Accessed 18 April 2024)

Roviš D, Černelič Bizjak M, Vasiljev Marchesi V, Petelin A, Jenuš T, Vidic S, and sur.. Increased Risk-Taking Behaviour and Brain-Derived Neurotrophic Factor Val66Met Polymorphism Correlates to Decreased Serum Brain-Derived Neurotrophic Factor Level in Heroin Users. European Addiction Research [Internet]. 2018 [cited 2024 April 18];24(4):189-200. Available at: https://urn.nsk.hr/urn:nbn:hr:184:728216

D. Roviš, et al., "Increased Risk-Taking Behaviour and Brain-Derived Neurotrophic Factor Val66Met Polymorphism Correlates to Decreased Serum Brain-Derived Neurotrophic Factor Level in Heroin Users", European Addiction Research, vol. 24, no. 4, pp. 189-200, 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:728216. [Accessed: 18 April 2024]

Metadata
Title (english)Increased Risk-Taking Behaviour and Brain-Derived Neurotrophic Factor Val66Met Polymorphism Correlates to Decreased Serum Brain-Derived Neurotrophic Factor Level in Heroin Users
AuthorDarko Roviš
AuthorMaša Černelič Bizjak
AuthorVanja Vasiljev Marchesi
AuthorAna Petelin
AuthorTina Jenuš
AuthorSuzana Vidic
AuthorGorazd Drevenšek
AuthorZala Jenko Pražnikar
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Social Medicine and Epidemiology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Public Health and Health Care
Abstract (english)
Background: This study has examined the relationships and interactions between serum brain-derived neurotrophic factor (BDNF) levels, BDNF Val66Met polymorphism and self-reported risk-taking behaviour in individuals with a history of heroin use undergoing outpatient treatment in comparison to healthy individuals. Methods: We enrolled 167 heroin users and 86 healthy subjects and examined serum BDNF levels, Val66Met polymorphism, and personal characteristics using Connor Davidson Resilience Scale, Risk-taking (RT) propensity questionnaire, and Personality Assessment Inventory. Results: Heroin users had significantly higher serum BDNF levels than controls. In addition, serum BDNF levels were significantly higher in Val/Val carriers than in Met/Val or Met/Met in all recruited subjects. Furthermore, a stepwise multiple regression analysis of serum BDNF levels as a dependent variable with related factors showed that in heroin users, Alcohol Use Disorder Identification Test score, anxiety and RT score were found as independent contributors to serum BDNF levels. When performing gene-environment interaction it was additionally found that heroin users with self-reported high risk-taking behaviour had significantly lower levels of serum BDNF among heroin users with the Met allele. Conclusions: These results indicate that genetic variant Met66 decreased the serum BDNF levels in combination with self-reported risk-taking propensity among heroin users. If results of future work confirm the influence of this combined effect between neurotrophic genotype and risk-taking behaviour, 66Met carriers might require higher levels of intervention to overcome their drug use pattern and risky behaviour.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleEuropean Addiction Research
Numberingvol. 24, no. 4, pp. 189-200
p-ISSN1022-6877
e-ISSN1421-9891
URN:NBNurn:nbn:hr:184:728216
Publication2018
Document URLhttp://bib.irb.hr/951532
Type of resourceText
Access conditionsRestricted access
Terms of useLicence In copyright icon
Created on2022-02-23 09:46:25